Article Text

Download PDFPDF

OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn’s disease patients from the open-label extension study
  1. M Ferrante1,
  2. J Panes2,
  3. F Baert3,
  4. E Louis4,
  5. A Kaser5,
  6. D Gustafson6,
  7. D Hall7,
  8. WO Böcher7,
  9. I Herichova7,
  10. X Liao6,
  11. K Wallace6,
  12. J Kalabic8,
  13. G D’Haens
  1. 1University Hospitals Leuven, Leuven, Belgium
  2. 2Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
  3. 3AZ Delta Roeselare-Menen, Roeselare, Belgium
  4. 4University of Liege and CHU, Liege, Belgium
  5. 5University of Cambridge, Cambridge, UK
  6. 6AbbVie Inc., North Chicago, USA
  7. 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
  8. 8AbbVie Deutschland GmbH and Co. KG, Ludwigshafen, Germany
  9. 9Academic Medical Center, Amsterdam, Netherlands


Introduction Adults with moderate-to-severe Crohn’s disease (CD) who responded to risankizumab (RZB) in the phase 2 induction and maintenance study (Feagan, 2017) could enroll in an open-label extension (OLE) study. Interim efficacy and safety of RZB maintenance treatment from the OLE, up to 2 years, are reported.

Methods Patients (pts) achieving clinical response (decrease from baseline [BL] in CD Activity Index [CDAI] ≥100) without remission (CDAI <150) after wk 26 or clinical response and/or remission after wk 52 of the preceding study received 180 mg s.c. RZB every 8 wks for up to 216 weeks. Pts losing clinical response or remission after completing the preceding study were re-induced with 600 mg i.v. RZB at wk 0, 4, 8. Pts received subsequent 180 mg s.c. RZB maintenance treatment only if they achieved response or remission following re-induction treatment. Ileocolonoscopy was performed yearly. Efficacy data (clinical remission and endoscopic remission [CD Endoscopic Index of Severity (CDEIS) ≤4 or CDEIS ≤2 for pts with initial isolated ileitis]) are reported up to wk 48. Non-responder imputation (NRI) was used for missing data.

Results A total of 65 pts were enrolled (including 4 who were re-induced). Mean (standard deviation) exposure to RZB was 657.2 (190.73) days. At the data cut-off, 14 (21.5%) pts have discontinued the study. Up to wk 48, clinical remission rates were sustained and the proportion of pts with endoscopic remission increased from BL (table 1). Adverse events (AEs) were reported for 58 (89.2%) pts; 18(27.7%) pts had serious AEs. AEs occurring in >10% of pts were nasopharyngitis (26.2%), fatigue (16.9%), arthralgia and worsening CD (15.4% each). Four serious infections in 5 pts were perianal abscess (n=1), Campylobacter (n=1), viral gastroenteritis (n=2), and peritonitis (n=2). No events of tuberculosis, malignancies or deaths occurred.

Conclusions In this interim analysis, clinical remission and endoscopic remission were sustained in CD pts receiving long-term RZB treatment. The safety profile of RZB was consistent with previously published data (Feagan, 2017).

Abstract OWE-05 Table 1

Pts in the OLE achieving clinical remission and endoscopic remission by visit


  1. Feagan BG, et al. Lancet 2017,29;389(10080):1699–1709.

  2. Feagan BG, et al. Gastroenterology 2017;152(5):S1310.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.